Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE).

@article{Lisak1983EffectOT,
  title={Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE).},
  author={Robert P. Lisak and Burton Zweiman and Nadine Blanchard and Lucy Balian Rorke},
  journal={Journal of the neurological sciences},
  year={1983},
  volume={62 1-3},
  pages={281-93}
}
Injections of Copolymer 1 (Cop-1), a synthetic cathodic polymer, have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis (MS). It has been suggested that the therapeutic effect is due to cell-mediated immune (CMI) cross-reactivity between Cop-1 and myelin basic protein (MBP), the antigen that induces EAE. We found that Cop-1 treatment of guinea pigs (GP) sensitized with MBP in adjuvant (20 micrograms/animal): (a… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
Injections of Copolymer 1 ( Cop-1 ) , a synthetic cathodic polymer , have been reported to prevent and treat successfully acute and recurrent EAE and has been employed in patients with multiple sclerosis ( MS ) .
All Topics